The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Blockchain is changing how the world does business, whether you’re ready or not. Learn from the experts at Business of Blockchain 2019.Register now
Genome engineers made more than 13,000 CRISPR edits in a single cell
A team at George Church’s Harvard lab wants to redesign species with large-scale DNA changes.
CRISPR experts are calling for a global moratorium on heritable gene editing
Some of the biggest names in gene editing want to stop anyone from playing around with cells that pass on changes to the next generation.
23andMe thinks polygenic risk scores are ready for the masses, but experts aren’t so sure
A new genetic test that estimates your risk for diabetes is probably less useful than standing on a scale.